Abstract: A liquid crystal composition for liquid crystal lens and a stereoscopic (3D) display containing the same are provided. The liquid crystal composition includes a main liquid crystal (chemical formula I), a first optical modifier (R811 or S811), a second optical modifier (CB15), and a dielectric constant modifier (chemical formula IV). The 3D display utilizes a horizontal electric field to make the above liquid crystal composition form crystal lens.

Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

Abstract: Bi- and tri-aromatic compounds of the formula (I) wherein R1 to RIO and X are as defined, are Nox2 inhibitors that are useful as medicaments for the treatment of a disease or condition selected from: cardiovascular diseases, respiratory diseases, inflammatory diseases, cancers, ageing and age related disorders, kidney diseases, neurodegenerative diseases, diabetes and conditions associated with diabetes. The compounds, their preparation and pharmaceutical compositions comprising them are disclosed.

Abstract: A novel material of a binaphthyl compound represented by General Formula (G1) is provided. Ar11 and Ar12 independently represent a substituted or unsubstituted arylene group having 6 to 12 carbon atoms, a substituted or unsubstituted cycloalkylene group having 3 to 12 carbon atoms, or a substituted or unsubstituted cycloalkenylene group having 3 to 12 carbon atoms, m represents 1 or 2, and n represents any one of 0 to 2. R12 represents a substituted or unsubstituted alkylene group having 1 to 12 carbon atoms, or a single bond. R13 represents hydrogen, a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms, or a substituted or unsubstituted alkoxy group having 1 to 12 carbon atoms. One of R10 and R11 represents a substituent represented by General Formula (G2), and the other represents hydrogen.

Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerizable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (“polymer sustained alignment”) type.

Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.

Abstract: Chiral liquid crystal compounds of the general formula (1): in which at least one of R1 and R2 is a chiral substituent, K may be a single bond or the same as K1-5 and K1-5 denote a six-membered ring system which rings may be at least partially unsaturated, wherein the number of atoms in these rings or ring systems between the two atoms forming a part of the link to the next ring, or to one of the substituents R1 and R2, does not differ by more than one if counted in the clockwise, and in the counter-clockwise sense, starting from the same atom in each case, X1-20 denote alkyl, or alkoxy, or fluorinated alkyl, or fluorinated alkoxy groups, or atom H, or halogen atoms, mixtures comprising such chiral liquid crystal compounds, and liquid crystal displays comprising such mixtures as active ingredients.

Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.

Abstract: A liquid crystal compound having high stability to heat, light and so forth, a high clearing point, a low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. The compound is represented by formula (1-1): wherein, for example, R1 is alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 2 to 10 carbons; R2 is alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 3 to 10 carbons; ring A1 is 1,4-cyclohexylene or 1,4-phenylene; ring A2 is 1,4-cyclohexylene, 1,4-phenylene or 2,3-difluoro-1,4-phenylene; Z1 and Z2 are single bonds; L1 and L2 are fluorine; and 1 is 0, 1 or 2.

Abstract: The present invention relates to arylated camphenes, processes for their preparation and uses thereof for the manufacture of medicaments for the treatment of diseases, disorders or conditions associated with, or benefiting from stimulation of CB2 receptors.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alko

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Abstract: Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen-containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed.

Abstract: The present invention relates to compounds represented by the following Formula Ic, in which R2-R6 can each independently be selected from hydrogen or hydrocarbyl (e.g., methyl); L1 and L4 are each independently a divalent linking group, such as a bond or —OC(O)—R8—C(O)O—, where R8 can be divalent hydrocarbyl (e.g., —CH2CH2—); each L2 and each L5 each independently represent a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 and each L6 each independently represent a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t and s are each independently from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; q and r are each independently from 0 to 4 for each s, provided that the sum of q and r is at least 1 for each s; and E1 and E2 can each independently be hydrogen or hydrocarbyl.

Abstract: A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.

Abstract: The invention concerns processes for the synthesis of a compound of the formula: wherein: R1 and R2 are each, independently, C1-C12 alkyl, CO2R3, OR4, R5(OR6), or C6-C18 aryl; R3-R6 are each, independently, C1-C12 alkyl or C6-C12 aryl; and n and m are each, independently, O or an integer from 1-5; said process comprising:—contacting a compound of the formula H0-R7-0H with BH3 and a compound of the formula in the presence of a nickel-containing catalyst to produce a first product, where R7 is a C2-C12 hydrocarbon group and X is a halogen, OMs or OTs;—contacting the first product in situ with a compound of the formula: in the presence of a nickel-containing catalyst to produce a compound of formula I, where Z is a halogen.

Abstract: Chiral liquid crystal compounds of the general formula (1): in which at least one of R1 and R2 is a chiral substituent, K may be a single bond or the same as K1-5 and K1-5 denote a six-membered ring system which rings may be at least partially unsaturated, wherein the number of atoms in these rings or ring systems between the two atoms forming a part of the link to the next ring, or to one of the substituents R1 and R2, does not differ by more than one if counted in the clockwise, and in the counter-clockwise sense, starting from the same atom in each case, X1-20 denote alkyl, or alkoxy, or fluorinated alkyl, or fluorinated alkoxy groups, or atom H, or halogen atoms, mixtures comprising such chiral liquid crystal compounds, and liquid crystal displays comprising such mixtures as active ingredients

Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.

Abstract: The present invention relates to photo-crosslinkable liquid crystal monomers with optical activity. The liquid crystal monomers contains one chiral center with an acrylate group or terminal diacrylate groups, and terminal dibenzene rings are introduced in order to extend its hard segment for the purpose of getting a wider liquid crystalline phase. By introducing the liquid crystal monomers, the room temperature nematic liquid crystal or the cholesteric liquid crystal may have a better mutual solubility and a wider, steadier structure of liquid crystal.

Abstract: An optically active bisbenzyl compound or a racemic bisbenzyl compound represented by formula (2) that has axial chirality. An optically active azepine derivative or a racemic azepine derivative represented by formula (3). Methods of producing an optically active quaternary ammonium salt compound represented by formula (8).

Abstract: The present disclosure provides a series of compounds which exhibit isoform selective inhibition of GRP94, a homologue of Hsp90 that is localized to the endoplasmic recticulum. Through GRP94 inhibition, these compounds are likely to manifest anti-cancer, anti-inflammatory, anti-metastasis, and immunosuppressive activities, as well as utility in the treatment of neurodegenerative diseases, and diabetes.

Abstract: The present invention relates to compounds represented by the following Formula Ia, in which each R1-R6 can in each case be independently selected from hydrogen or hydrocarbyl (e.g., methyl); R7 is a multivalent linking group, such as L1 is a divalent linking group, such as a bond or divalent optionally substituted hydrocarbyl; each L2 independently represents a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 independently represents a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t is from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; and E can be hydrogen or optionally substituted hydrocarbyl. The present invention also relates to compositions, such as liquid crystal compositions, and articles, such as optical elements, that include the compound represented by Formula Ia.

Abstract: A compound shown by the following formula (1).

Abstract: The present invention relates to novel 4-biphenyl-substituted pyrazolidine-3,5-dione derivatives of the formula (I) in which A, D, G, W, X, Y and Z are as defined above, to a plurality of processes for the preparation and to their use as pesticides and/or herbicides and/or microbicides. Moreover, the invention relates to selective herbicidal compositions comprising both the 4-biphenyl-substituted pyrazolidine-3,5-dione derivatives of the formula (I) and a crop plant compatibility-improving compound.

Abstract: The present invention relates to compounds represented by the following Formula I, in which R1-R6 can each independently be selected from hydrogen or hydrocarbyl (e.g., methyl); L1 is a divalent linking group, such as a bond or —OC(O)—R8—C(O)O—, where R8 can be divalent hydrocarbyl (e.g., —CH2CH2—); each L2 independently represents a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 independently represents a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t is from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; and E can be hydrogen or hydrocarbyl. The present invention also relates to compositions, such as liquid crystal compositions, and articles, such as optical elements, that include the compound represented by Formula I.

Abstract: The invention relates to a new process for the synthesis of high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.

Abstract: The present invention relates to a compound as a peroxisome proliferator activated receptor (PPAR) activator and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, a cosmetic composition, a muscle strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.

Abstract: An optically anisotropic material having a good durability against light is provided. Further, an optical element having a good durability against light and an optical information writing/reading device employing such an element are provided. The optically anisotropic material is obtainable by polymerizing a polymerizable liquid crystal composition containing at least 5 mol % of at least one type of polymerizable compound represented by a general formula CH2?CR1—COO—K-Cy-Cy-L-OCO—CR2?CH2. A phase difference plate 4 produced by employing the optically anisotropic material has a good durability against light, and accordingly, the phase difference plate 4 can realize an optical heat device suitable for large capacity writing/reading by employing a blue laser as a light source 1.

Abstract: The present invention relates to arylated camphenes, processes for their preparation and uses thereof for the manufacture of medicaments for the treatment of diseases, disorders or conditions associated with, or benefiting from stimulation of CB2 receptors.

Abstract: A liquid crystal compound represented by formula (1-1). For example, R1 and R2 are independently hydrogen, alkyl having 1 to 10 carbons, alkenyl having 2 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons or alkenyloxy having 2 to 9 carbons; the ring A1 is trans-1,4-cyclohexylene, 1,4-cyclohexenylene, 1,3-dioxane-2,5-diyl, pyrimidine-2,5-diyl or pyridine-2,5-diyl; L1 and L2 are independently hydrogen or fluorine, and at least one of them is fluorine; and Z1, Z2 and Z3 are independently a single bond, —(CH2)2—, —CH?CH—, —C?C—, —CH2O—, —OCH2—, —COO— or —OCO—.

Abstract: Novel resorcinol derivatives and methods of preparation and use are presented. These compounds can stimulate angiogenesis as a biological function triggered by the activation of one cannabinoid receptor distinct from CB1 and CB2. Thus, these compounds are specific ligands for one cannabinoid receptor distinct from CB1 and CB2. The invented compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions.

Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.

Abstract: The racemic and chiral compounds expressed by common formula 1 and formula 2: wherein the lateral substituents X1, X2, X3, X4, X5, X6, X7 and X8 in the benzene rings represent independently hydrogen and fluorine atoms, bridge group Z represent independently the single bond or COO, CH2CH2, CH2O and OCH2 group, substituent Y represents CH3, or CH2F, CHF2, CF3, C2H5 group, symbols n, m, r and t are independently integers of 1 to 8; symbols p and s signify independently number of 0 to 1 and its orthoconic antiferroelectric long helical pitch mixtures prepared by the methods 1) to the racemic components selected from compounds 1 are added chiral components selected from the compound of formula 1 and/or chiral components selected from the compounds of formula 2 and/or another optically active compounds with high helical twisting power, 2) to chiral compound 1 which helical pitches increases with the temperature increase is added chiral compound 1 which helical pitch decreases with temperature increase.

Abstract: A photosensitive compound whose size is smaller than conventional polymer for photoresist, and which has well-defined (uniform) structure, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 10 to 5000 weight parts of an organic solvent. In the formula, n is 0 or 1, x is 1, 2, 3, 4 or 5, y is 2, 3, 4, 5 or 6, z is 0, 1, 2, 3 or 4, R, R? and R? are independently hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms, and R?? is a hydrogen atom or hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms.

Abstract: The subject is to provide a liquid crystal that has a high stability to heat, light and so forth, a wide temperature range of a nematic phase, a small viscosity, a large optical anisotropy and a suitable elastic constant K33, and further has a large negative dielectric anisotropy and an excellent compatibility with any other liquid crystal compound. The invention provides the compound (1): wherein, for example, R1 and R2 are hydrogen, alkyl having 1 to 10 carbons, alkenyl having 2 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons or alkenyloxy having 2 to 9 carbons; when one of the ring A1, the ring A2 and the ring A3 is 1,4-phenylene or 2,3-difluoro-1,4-phenylene, the other two are 1,4-cyclohexylene or 1,4-cyclohexenylene; and Z1 is a single bond, —(CH2)2—, —CH2O—, —OCH2—, —COO— or —OCO—.

Abstract: Chiral liquid crystal compounds of the general formula (1): in which at least one of R1 and R2 is a chiral substituent, K may be a single bond or the same as K1-5 and K1-5 denote a six-membered ring system which rings may be at least partially unsaturated, wherein the number of atoms in these rings or ring systems between the two atoms forming a part of the link to the next ring, or to one of the substituents R1 and R2, does not differ by more than one if counted in the clockwise, and in the counter-clockwise sense, starting from the same atom in each case, X1-20 denote alkyl, or alkoxy, or fluorinated alkyl, or fluorinated alkoxy groups, or atom H, or halogen atoms, mixtures comprising such chiral liquid crystal compounds, and liquid crystal displays comprising such mixtures as active ingredients

Abstract: The invention concerns processes for the synthesis of a compound of the formula: wherein: R1 and R2 are each, independently, C1-C12 alkyl, CO2R3, OR4, R5(OR6), or C6-C18 aryl; R3-R6 are each, independently, C1-C12 alkyl or C6-C12 aryl; and n and m are each, independently, O or an integer from 1-5; said process comprising: —contacting a compound of the formula H0-R7-0H with BH3 and a compound of the formula in the presence of a nickel-containing catalyst to produce a first product, where R7 is a C2-C12 hydrocarbon group and X is a halogen, OMs or OTs; —contacting the first product in situ with a compound of the formula: in the presence of a nickel-containing catalyst to produce a compound of formula I, where Z is a halogen.

Abstract: The present invention relates to compounds of structural formula I as site-specific inhibitors of histone methyltransferase, where R1 and R1 is —OCH3 or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula Ia, where R1 and R1 is —OCH3, R2 and R2 is —OH; a process of preparation of compound of structural formula Ib, where R1 and R1 is —OCH3, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.

Abstract: The present invention relates to a radial-shaped liquid crystal compound, and an optical film and a liquid crystal display device comprising the same. Particularly the present invention provides a compound represented by Chemical Formula 1 comprising a radial-shaped core of tetraphenyl ethylene in which four phenyl groups are bonded to an ethylene group, and makes it possible to provide an optical film which can minimize the change of color according to viewing angle and has an improved contrast ratio and high refractive anisotropy, and a liquid crystal display device comprising the same, by using the compound.

Abstract: An optically anisotropic material comprising at least one discotic compound having a cyclopropylcarbonyl group. The material is excellent in both the wavelength dispersion property and the refractive index anisotropy.

Abstract: A compound shown by the following formula (1).

Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.

Abstract: The invention provides a liquid crystal compound which has stability to heat, light and so forth, a nematic phase in a wide temperature range, a small viscosity, a large optical anisotropy, and a suitable elastic constant K33, and further has a suitable and negative dielectric anisotropy and an excellent compatibility with other liquid crystal compounds. Moreover, the invention provides a liquid crystal composition comprising this liquid crystal compound and a liquid crystal display device containing this liquid crystal composition. A liquid crystal compound represented by formula (a): for example, R1 and R2 are alkyl having 1 to 10 carbons, alkenyl having 2 to 10 carbons or alkoxy having 1 to 9 carbons; ring A1 and ring A2 are 1,4-phenylene or trans-1,4-cyclohexylene; L1 and L2 are hydrogen or fluorine, and at least one of L1 and L2 is fluorine; and Z1 and Z2 are a single bond, —(CH2)2—, —CH?CH—, —CH2O— or —OCH2—.

Abstract: The present invention relates to compounds of structural formula I as site-specific inhibitors of histone methyltransferase, where R1 and R1 is —OCH3 or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula Ia, where R1 and R1 is —OCH3, R2 and R2 is —OH; a process of preparation of compound of structural formula Ib, where R1 and R1 is —OCH3, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.

Abstract: Liquid crystal compositions comprising compounds including at least one mesogenic substructure and at least one long flexible segment and a compound selected from a photochromic compound, a dichroic compound and a photochromic-dichroic compound and methods of synthesizing the same and their use in articles of manufacture and ophthalmic devices are disclosed.

Abstract: Compounds including at least one mesogenic substructure and at least one long flexible segment and methods of synthesizing the same are disclosed. Formulations which include various embodiments of the mesogen containing compounds and their use in articles of manufacture and ophthalmic devices are also disclosed.

Abstract: The present invention relates to a process for the preparation of compounds of formula (I), wherein the substituents are as defined in claim 1, by reacting a compound of formula (II), with a bromine or chlorine source to form a compound of formula (III), wherein X is chlorine or bromine; reacting that compound with water to form the compound of formula (IV), converting that compound, using a compound of formula (V), wherein M+ is the hydrogen cation or an alkali metal ion, alkaline earth metal ion or ammonium ion, into the compound of formula (VI), and treating that compound with a cyanide source in the presence of a base.

Abstract: The present invention relates to compounds of structural formula I as site-specific inhibitors of histone methyltransferase, where R1 and R1 is —OCH3 or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula Ia, where R1 and R1 is —OCH3, R2 and R2 is —OH; a process of preparation of compound of structural formula Ib, where R1 and R1 is —OCH3, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.

Abstract: The present invention relates to compounds of structural formula (I) as site-specific inhibitor of histone methyl-transferase, where R1 and R1 is —OCH or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula (Ia), where R1 and R1 is —OCH, R2 and R2 is —OH; a process of preparation of compound of structural formula (Ib), where R1 and R1 is —OCH, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.